In addition, Imugene has made strides in expanding its trial. The Cohort Review Committee has cleared the first cohort of ...

Imugene (ASX:IMU) has announced that a bile tract cancer patient in its Phase 1 MAST trial remains a complete response, now ...

Imugene Limited (AU:IMU) has released an update. Imugene Limited has reached a significant milestone in its MAST trial, with a bile tract ...

Big news is giving this stock an even bigger lift on Tuesday. What's happening? The post Guess which ASX 300 stock is jumping ...

Clinical-stage immuno-oncology company Imugene is celebrating more than two years’ “complete response” for one of its bile ...

Imugene stocks well placed to grow with clinical progress on azer-cel CAR T-cell therapy and strong cash position, say analysts ...

Imugene Limited (AU:IMU) has released an update. Imugene Limited has reported promising progress in its clinical trials, including three ...

The first cohort of three patients in the Bile Tract Cancer Expansion of the VAXINIA trial has been cleared, with no safety concerns or dose-limiting toxicities. The trial is now open for full ...

Two All Ords ASX healthcare shares are making big moves, one racing ahead of the All Ordinaries Index (ASX: XAO) and one far ...

The first cohort of three patients in the Bile Tract Cancer Expansion of the VAXINIA trial has been cleared, with no safety concerns or dose-limiting toxicities. The trial is now open for full ...

The trial, which uses the innovative CF33-hNIS (VAXINIA) virus, has cleared its first cohort for safety, opening doors for further patient enrollment. With FDA Fast Track and Orphan Drug ...

It is evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). According to the release, a bile tract cancer patient in Imugene's Phase 1 MAST trial remains a complete ...